- 0 Comments
Production and Characterization of a Camelid Single Domain Antibody−Urease Enzyme Conjugate for the Treatment of Cancer LDOS47-Bioconjugate-May-2015.pdf LDOS47-Bioconjugate-May-2015-1.pdf
Production and Characterization of a Camelid Single Domain Antibody−Urease Enzyme Conjugate for the Treatment of Cancer LDOS47-Bioconjugate-May-2015.pdf LDOS47-Bioconjugate-May-2015-1.pdf
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its Chief Scientific Officer, Dr. Heman Chao, has been invited to give an oral presentation at the 2015 Joint Conference of the Canadian Society For Pharmaceutical Science and the […]
05192015-HBP-Press-Release-Retains-The-Trout-Group-as-Investor-Relations-Advisor.pdf
05142015-HBP-Press-Release-Announces-Publication-PeerReviewed-LDOS47.pdf
04292015-HBP-Press-Release-Closes-Additional-Private-Placement-Financing.pdf
HBP Press Release – Initiates Enrollment for Twelvth Cohort in Polish Phase I,II Clinical Study
HBP Press Release – Receipt of net CAD5.2mil Private Placement Subscriptions